In 2021, even the most vulnerable economies will have access to vaccines: WHO

COVAX increased its agreements for the vaccination program for the most vulnerable people globally, reaching 2 billion doses.
In 2021, even the most vulnerable economies will have access to vaccines: WHO
Image credit:

Entrepreneur's New Year’s Guide

Let the business resources in our guide inspire you and help you achieve your goals in 2021.
Entrepreneur Staff
3 min read
This article was translated from our Spanish edition using AI technologies. Errors may exist due to this process.
  • This news came after COVAX's initiative to bring vaccines to “developing” countries was seen as underfunded and underfunded.

The World Health Organization (WHO) announced that its global vaccine delivery mechanism, COVAX, "now has agreements to access nearly 2 billion doses of various promising candidate vaccines," so its supplies have been increased from meaningful way.

Additionally, it is estimated that at least 1.3 billion doses will be delivered "to the 92 low- and middle-income economies eligible for COVAX AMC (Advance Market Commitment)."

It is worth mentioning that this news came after the COVAX initiative to bring vaccines to “developing” countries was deemed to have scarce funding and contracts. Some experts even pointed out that the chances that COVID-19 vaccines would be distributed fairly were fading fast.

However, the new agreements represent good news as, according to a statement, "the first deliveries are expected to begin in the first quarter of 2021, depending on regulatory approvals and the preparation of countries for delivery," thus protecting , “To the most vulnerable populations around the world”.

Among the Latin American nations that will obtain donations through COVAX are Bolivia, El Salvador, Haiti, Nicaragua, Honduras, Saint Lucia and Saint Vincent and the Grenadines. Although, all Latin American and Caribbean countries are also expected to receive vaccines at the same time (whether they pay or not).

Likewise, the new commitments that were announced contemplate the anticipated purchase of 170 million doses of the vaccine developed by AstraZeneca and 500 million doses from the pharmaceutical company Janssen of Johnson & Johnson, which recently and successfully completed the study of its vaccine in Colombia.

More from Entrepreneur

Get heaping discounts to books you love delivered straight to your inbox. We’ll feature a different book each week and share exclusive deals you won’t find anywhere else.
Amplify your business knowledge and reach your full entrepreneurial potential with Entrepreneur Insider’s exclusive benefits. For just $5 per month, get access to premium content, webinars, an ad-free experience, and more! Plus, enjoy a FREE 1-year Entrepreneur magazine subscription.
Create your business plan in half the time with twice the impact using Entrepreneur's BIZ PLANNING PLUS powered by LivePlan. Try risk free for 60 days.

Latest on Entrepreneur